SBI Securities Co. Ltd. acquired a new position in shares of CVS Health Co. (NYSE:CVS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,351 shares of the pharmacy operator's stock, valued at approximately $195,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hotchkis & Wiley Capital Management LLC grew its stake in CVS Health by 34.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 11,897,034 shares of the pharmacy operator's stock valued at $748,085,000 after acquiring an additional 3,071,613 shares in the last quarter. ARGA Investment Management LP grew its stake in shares of CVS Health by 7,567.7% in the 4th quarter. ARGA Investment Management LP now owns 2,402,901 shares of the pharmacy operator's stock valued at $107,866,000 after buying an additional 2,371,563 shares in the last quarter. State Street Corp grew its stake in shares of CVS Health by 3.6% in the 3rd quarter. State Street Corp now owns 56,527,909 shares of the pharmacy operator's stock valued at $3,554,475,000 after buying an additional 1,989,066 shares in the last quarter. TOMS Capital Investment Management LP bought a new stake in shares of CVS Health in the 3rd quarter valued at approximately $121,987,000. Finally, Mizuho Markets Americas LLC grew its stake in shares of CVS Health by 1,470.2% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,396,464 shares of the pharmacy operator's stock valued at $87,810,000 after buying an additional 1,307,531 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.
CVS Health Stock Performance
Shares of CVS stock traded up $1.09 during trading hours on Friday, reaching $66.34. 10,082,148 shares of the company's stock were exchanged, compared to its average volume of 11,965,158. The business has a fifty day moving average price of $56.42 and a 200-day moving average price of $56.73. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $83.64 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.98 and a beta of 0.54. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75.
CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.
CVS Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.01%. CVS Health's dividend payout ratio is currently 72.68%.
Analysts Set New Price Targets
Several equities research analysts recently commented on CVS shares. Piper Sandler lowered their price target on CVS Health from $72.00 to $64.00 and set an "overweight" rating for the company in a research note on Monday, November 25th. Argus set a $77.00 price target on CVS Health in a research note on Tuesday, February 18th. TD Cowen boosted their price target on CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a research note on Monday, November 25th. Evercore ISI upped their target price on CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research report on Monday, January 27th. Finally, Edward Jones raised CVS Health from a "hold" rating to a "buy" rating in a research report on Thursday, January 30th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, CVS Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $69.83.
Get Our Latest Analysis on CVS
Insiders Place Their Bets
In other CVS Health news, Director Michael F. Mahoney bought 30,000 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the acquisition, the director now owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company's stock.
CVS Health Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Articles
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
